Inventor · disambiguated record
Srinivas Laxminarayan Pathi
Also filed as: PATHI SRINIVAS LAXMINARAYAN
29 granted patents·10 pending applications·24 citations·filing 2005–2022
93Inventor score
Files withCIPLA LTD26KANKAN RAJENDRA NARAYANRAO4PATHI SRINIVAS LAXMINARAYAN4RAO DHARMARAJ RAMACHANDRA4PUPPALA RAVIKUMAR1
Top patents by PatentIndex Score
39 records- 0189US10301282B2Polymorphic form X of nilotinib dihydrochloride hydrateCIPLA LTD·Filed 2016·Granted May 28, 2019·6 cites·15 claims
- 0282US8394963B2Process for the preparation of esomeprazole magnesium dihydrateRAO DHARMARAJ RAMACHANDRA·Filed 2008·Granted Mar 12, 2013·4 cites·8 claims
- 0381US8076492B2Process for preparing trityl olmesartan medoxomil and olmesartan medoxomilPATHI SRINIVAS LAXMINARAYAN·Filed 2007·Granted Dec 13, 2011·4 cites·28 claims
- 0479US7989636B2Process for the preparation of pure anastrozoleCIPLA LTD·Filed 2007·Granted Aug 2, 2011·2 cites·29 claims
- 0577US8133996B2Process for the preparation of ethyl-N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloridePATHI SRINIVAS LAXMINARAYAN·Filed 2008·Granted Mar 13, 2012·3 cites·12 claims
- 0674US8912337B2Salts and polymorphs of dexrabeprazoleRAO DHARMARAJ RAMACHANDRA·Filed 2011·Granted Dec 16, 2014·1 cites·22 claims
- 0773US8258294B2Process for the preparation of temozolomide and analogsPATHI SRINIVAS LAXMINARAYAN·Filed 2007·Granted Sep 4, 2012·1 cites·27 claims
- 0870US8003804B2Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediateCIPLA LTD·Filed 2007·Granted Aug 23, 2011·1 cites·3 claims
- 0967US8269003B2Stable crystal form of imatinib mesylate and process for the preparation thereofPATHI SRINIVAS LAXMINARAYAN·Filed 2005·Granted Sep 18, 2012·1 cites·8 claims
- 1067US7799928B2Process for the preparation of irbesartan hydrochlorideCIPLA LTD·Filed 2005·Granted Sep 21, 2010·1 cites·40 claims
- 1161US8288561B2Process for preparing valsartanKANKAN RAJENDRA NARAYANRAO·Filed 2008·Granted Oct 16, 2012·0 cites·11 claims
- 1260US2015080579A1Salts and Polymorphs of DexrabeprazoleCIPLA LTD·Filed 2014·Application pending·0 cites
- 1358US8350029B2Process for the preparation of gefitinibCIPLA LTD·Filed 2008·Granted Jan 8, 2013·0 cites·20 claims
- 1457US8344149B2Crystalline form of benzothiophene compound and process for preparation thereofCIPLA LTD·Filed 2007·Granted Jan 1, 2013·0 cites·17 claims
- 1557US8242269B2Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processesKANKAN RAJENDRA NARAYANRAO·Filed 2008·Granted Aug 14, 2012·0 cites·10 claims
- 1657US2024059661A1Solid state forms of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereofCIPLA LTD·Filed 2022·Application pending·0 cites
- 1757US2013150587A1Process for the Preparation of Esomeprazole Magnesium DihydrateCIPLA LTD·Filed 2013·Application pending·0 cites
- 1854US8987458B2Process for the preparation of donepezil hydrochlorideRAO DHARMARAJ RAMACHANDRA·Filed 2009·Granted Mar 24, 2015·0 cites·17 claims
- 1954US2023212115A1Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forme thereofCIPLA LTD·Filed 2021·Application pending·0 cites
- 2052US8198451B2Process for the synthesis of moxifloxacin hydrochlorideRAO DHARMARAJ RAMACHANDRA·Filed 2007·Granted Jun 12, 2012·0 cites·15 claims
- 2152US2015359898A1Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed ComplexesCIPLA LTD·Filed 2014·Application pending·0 cites
- 2251US8030491B2Process and intermediate for preparation of donepezilCIPLA LTD·Filed 2007·Granted Oct 4, 2011·0 cites·20 claims
- 2351US7638633B2Process for synthesis of proton pump inhibitorsCIPLA LTD·Filed 2006·Granted Dec 29, 2009·0 cites·10 claims
- 2451US2023075170A1Novel salts of nilotinib and polymorphic forms thereofCIPLA LTD·Filed 2021·Application pending·0 cites
- 2550US12195480B2Polymorphs of integrase inhibitorCIPLA LTD·Filed 2020·Granted Jan 14, 2025·0 cites·10 claims
- 2650US2020407382A1Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereofCIPLA LTD·Filed 2018·Application pending·0 cites
- 2750US2010081688A1Process for the preparation of montelukast, and intermediates thereforCIPLA LTD·Filed 2007·Application pending·0 cites
- 2849US9890121B2Process for preparing atazanavir sulphateCIPLA LTD·Filed 2014·Granted Feb 13, 2018·0 cites·18 claims
- 2949US8349863B2Crystalline polymorphic form of a camptothecin analogueCIPLA LTD·Filed 2006·Granted Jan 8, 2013·0 cites·19 claims
- 3048US12384784B2Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitorCIPLA LTD·Filed 2019·Granted Aug 12, 2025·0 cites·6 claims
- 3147US7951837B2Crystalline forms of duloxetine free baseCIPLA LTD·Filed 2005·Granted May 31, 2011·0 cites·6 claims
- 3245US10023611B2Process for the preparation of bortezomib mannitol esterCIPLA LTD·Filed 2014·Granted Jul 17, 2018·0 cites·18 claims
- 3345US9505787B2Process for preparing of bortezomibCIPLA LTD·Filed 2013·Granted Nov 29, 2016·0 cites·24 claims
- 3445US8691995B2ProcessKANKAN RAJENDRA NARAYANRAO·Filed 2005·Granted Apr 8, 2014·0 cites·20 claims
- 3542US8691999B2Process for the preparation of telmisartanKANKAN RAJENDRA NARAYANRAO·Filed 2005·Granted Apr 8, 2014·0 cites·21 claims
- 3641US10287248B2Process for the preparation of apremilastCIPLA LTD·Filed 2016·Granted May 14, 2019·0 cites·30 claims
- 3739US2022009929A1Polymorphic forms of ibrutinibCIPLA LTD·Filed 2019·Application pending·0 cites
- 3838US2019270735A1Polymorphs of DasatinibCIPLA LTD·Filed 2017·Application pending·0 cites
- 3934US9062049B2Process for the preparation of paliperidonePUPPALA RAVIKUMAR·Filed 2012·Granted Jun 23, 2015·0 cites·31 claims
Join the waitlist — get patent alerts
Get an alert when Srinivas Laxminarayan Pathi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →